Electra Therapeutics
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $183.0Mattributed |
|---|---|
| Latest round | series-c, $183.0M, 2025-10-01attributed |
| Founded | unknown |
| Headquarters | South San Francisco CA |
| Industry | biotech|immunology|oncology |
| Stage | series-b+ |
| Website | electratx.com |
Electra Therapeutics develops first-in-class monoclonal antibodies against signal regulatory proteins (SIRPs), led by ELA026 for secondary hemophagocytic lymphohistiocytosis, with ELA822 in T-cell disease. It treats sHLH (100% 8-week survival in Phase 1b) and hematologic cancers. Electra's antibodies spare the CD47/SIRPα checkpoint.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-c | $183.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $183.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $183.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | electratx.com, read 2026-05-05 |
| Description | self-reported | electratx.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.